tetano
Editor, Senior Moderator
Protein Expr Purif. 2011 Mar 18. [Epub ahead of print]
Insect larvae biofactories as a platform for influenza vaccine production.
Gomez-Casado E, Gomez-Sebastian S, N??ez MC, Lasa-Covarrubias R, Mart?nez-Pulgar?n S, Escribano JM.
Department of Biotechnology, Instituto Nacional de Investigaci?n y Tecnolog?a Agraria y Alimentaria (INIA). Autov?a A6, Km 7.5, 28040-Madrid, Spain.
Abstract
Increased production capacity is one of the most important priorities for seasonal and pandemic influenza vaccines. In the present study, we used a baculovirus-insect larvae system (considered small, living biofactories) to improve the production of recombinant influenza virus H1N1 hemagglutinin (HA). Insect larvae produced 4-fold more HA protein than insect cells per biomass unit (one gram of fresh larvae weight). A single infected Trichoplusia ni larva produced up to 113 μg of soluble and easily purified recombinant HA, an amount similar to that produced by 1.2 x 10(8) Sf21 insect cells infected by the same baculovirus. The use of the KDEL endoplasmic reticulum retention signal fused to the HA protein further increased recombinant protein production. Larvae-derived HA was immunogenically functional in vaccinated mice, inducing the generation of hemagglutination inhibition antibodies and a protective immune response against a lethal challenge with a highly virulent virus. The productivity, scalability and cost efficiency of small, living biofactories based on insect larvae suggest a broad-based strategy for the production of recombinant subunit vaccines against seasonal or pandemic influenza as an alternative to fermentation technologies.
Copyright ? 2011. Published by Elsevier Inc.
PMID: 21421054 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21421054
Insect larvae biofactories as a platform for influenza vaccine production.
Gomez-Casado E, Gomez-Sebastian S, N??ez MC, Lasa-Covarrubias R, Mart?nez-Pulgar?n S, Escribano JM.
Department of Biotechnology, Instituto Nacional de Investigaci?n y Tecnolog?a Agraria y Alimentaria (INIA). Autov?a A6, Km 7.5, 28040-Madrid, Spain.
Abstract
Increased production capacity is one of the most important priorities for seasonal and pandemic influenza vaccines. In the present study, we used a baculovirus-insect larvae system (considered small, living biofactories) to improve the production of recombinant influenza virus H1N1 hemagglutinin (HA). Insect larvae produced 4-fold more HA protein than insect cells per biomass unit (one gram of fresh larvae weight). A single infected Trichoplusia ni larva produced up to 113 μg of soluble and easily purified recombinant HA, an amount similar to that produced by 1.2 x 10(8) Sf21 insect cells infected by the same baculovirus. The use of the KDEL endoplasmic reticulum retention signal fused to the HA protein further increased recombinant protein production. Larvae-derived HA was immunogenically functional in vaccinated mice, inducing the generation of hemagglutination inhibition antibodies and a protective immune response against a lethal challenge with a highly virulent virus. The productivity, scalability and cost efficiency of small, living biofactories based on insect larvae suggest a broad-based strategy for the production of recombinant subunit vaccines against seasonal or pandemic influenza as an alternative to fermentation technologies.
Copyright ? 2011. Published by Elsevier Inc.
PMID: 21421054 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21421054